Synopsis
In Russia, allergic rhinitis affects 10-20 per cent of the population on average, with certain regions having a higher prevalence rate of 18-38 per cent. Allergic rhinitis can impact a person s quality of life and lead to functional impairments, as well as increase the risk of having asthma, the company said.
Agencies
Representative Image
Glenmark Pharma on Monday its Swiss subsidiary has received marketing approval from the Russian health regulator for its nasal spray Ryaltris. Ryaltris is indicated for symptomatic treatment of seasonal and perennial allergic rhinitis in adults and children over 12 years of age. The drug relieves symptoms of allergic rhinitis, including stuffy nose, runny nose, nasal itching, sneezing, as well as itchy, red and watery eyes.
Mumbai (Maharashtra) [India], February 22 (ANI/PRNewswire): Glenmark Pharmaceuticals Ltd. (Glenmark), a research-led global integrated pharmaceutical company, today announced that its Swiss subsidiary, Glenmark Specialty SA, received marketing approval from the Ministry of Health of the Russian Federation for its innovative Ryaltris® Nasal Spray - a novel fixed-dose combination nasal spray.
Glenmark arm gets Russian Health Ministry nod for nasal spray Ryaltris
February 22, 2021 Glenmark Pharmaceuticals on Monday said its Swiss subsidiary has received marketing approval from the Russian health regulator for its nasal spray Ryaltris.
Ryaltris is indicated for symptomatic treatment of seasonal and perennial allergic rhinitis in adults and children over 12 years of age. The drug relieves symptoms of allergic rhinitis, including stuffy nose, runny nose, nasal itching, sneezing, as well as itchy, red and watery eyes.
“Glenmark Specialty received marketing approval from the Ministry of Health of the Russian Federation for its innovative Ryaltris Nasal Spray a novel fixed-dose combination nasal spray. This paves the way for commercialisation of Ryaltris in Russia which is expected to be made available to patients in the country in Q1FY2021-22,” Glenmark Pharmaceuticals said in a regulatory filing.